Accelerate Your COVID-19 Bioanalytical Research While Saving Time and Reducing Cost
Erik Jerks
The pharmaceutical industry is in a race to treat and prevent COVID-19 from impacting more human lives. This has led to many alternative approaches, but regulated Bioanalytical is not an area where short cuts should be taken. We will discuss current approaches available for therapeutic and vaccine Bioanalytical assessments and regulatory requirements in clinical research.
As an alternative to the current gold standard of conventional virus neutralization tests, we will highlight a simple and rapid validated SARS-CoV-2 surrogate virus neutralization test (sVNT) that is amenable to high-throughput testing and/or fully automated by detecting total immunodominant neutralizing antibodies that can be rapidly conducted without requiring a biosafety level 3 containment.
Learning Objectives:
- Review current approaches available for therapeutic and vaccine assessments including COVID-19 bioanalytical analysis
- Learn how utilizing an alternative approach to Nab testing analysis can advance your research by saving you time and money
- Discuss regulatory impacts of emerging research, technology and how to accelerate your clinical trial program